Studies involving the GH-IGF axis: Lessons from IGF-I and IGF-I receptor gene targeting mouse models

Journal of Endocrinological Investigation

Volumn 28, Issue 5 SUPPL, 2005, Pages 19-22

  Yakar, S ^a   Pennisi, P ^a   Kim, C H ^a   Zhao, H ^a   Toyoshima, Y ^a   Gavrilova, O ^a   LeRoith, D ^a,b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Gene deletion mice models; IGF I; IGF I receptor; Transgenic mice

Indexed keywords

FATTY ACID; FIBRIC ACID DERIVATIVE; GROWTH HORMONE; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; TRIACYLGLYCEROL; SOMATOMEDIN C RECEPTOR;

BREAST CANCER; CANCER GROWTH; CIRCULATION; CLINICAL STUDY; COLON CANCER; CONFERENCE PAPER; DISEASE COURSE; DISEASE SEVERITY; FATTY ACID OXIDATION; GENE DELETION; GENE TARGETING; INCIDENCE; INSULIN RESISTANCE; LIVER METASTASIS; METASTASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKELETAL MUSCLE; TOXICITY; ANIMAL; DISEASE MODEL; GENETICS; MOUSE; MOUSE MUTANT; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GROWTH HORMONE; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, KNOCKOUT; NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 27744438744     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Daughaday WH, Hall K, Raben MS, Salmon WD Jr, van den Brande JL, van Wyk JJ. Somatomedin: proposed designation for sulphation factor. Nature 1972, 235: 107-9.
2. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis. Endocr Rev 2001, 22: 53-74.
3. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999, 96: 7324-9.
4. Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest 2002, 110: 771-81.
5. Yakar S, Liu JL, Fernandez AM, et al. Liver-specific IGF-I gene deletion leads to muscle insulin insensitivity. Diabetes 2001, 50: 1110-8.
6. Yakar S, Setser J, Zhao H, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-I-deficient mice. J Clin Invest 2004, 113: 96-105.
7. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4: 4505-18.
8. Wu Y, Yakar S, Zhao H, et al. Circulating IGF-I levels regulate colon cancer growth and metastasis. Cancer Res 2002, 62: 1030-5.
9. Wu Y, Cui K, Miyoshi K, et al. Reduced circulating IGF-I levels delays the onset of chemically- and genetically-induced mammary tumors. Cancer Res 2004, 63: 4348.
10. Kato H, Faria TN, Stannard B, Roberts CT Jr, LeRoith D. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J Biol Chem 1993, 268: 2655-61.
11. Fernandez AM, Kim JK, Yakar S, et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15:1926-34.
12. Kim H, Haluzik M, Asghar Z, et al. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes, 2003, 52: 1770-8.
13. Kim H, Haluzik M, Gavrilova O, et al. Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidemia without affecting the hyperglycemia in a transgenic model of type 2 diabetes. Diabetologia 2004, 47: 2215-25.
14. Zhao H, Yakar S, Gavrilova O, et al. Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes. Diabetes 2004, 53: 2901-9.